Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Eli Lilly and Company (LLY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 74,251,544
  • Shares Outstanding, K 1,103,950
  • Annual Sales, $ 19,959 M
  • Annual Income, $ 2,408 M
  • 36-Month Beta 0.23
  • Price/Sales 3.72
  • Price/Book 4.75

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.18 +4.99%
on 11/23/16
79.70 -15.46%
on 11/10/16
-6.50 (-8.80%)
since 11/07/16
3-Month
64.18 +4.99%
on 11/23/16
83.24 -19.05%
on 10/10/16
-11.21 (-14.26%)
since 09/07/16
52-Week
64.18 +4.99%
on 11/23/16
87.67 -23.14%
on 12/08/15
-19.00 (-22.00%)
since 12/07/15

Most Recent Stories

More News
Lilly: Jardiance Label to Add Cardiovascular Indication

Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's...

The Zacks Analyst Blog Highlights: Amazon, Dow Chemical, Ford, Eli Lilly and Eni

The Zacks Analyst Blog Highlights: Amazon, Dow Chemical, Ford, Eli Lilly and Eni

Top Research Reports for Amazon, Ford & Dow Chemical

Top Research Reports for Amazon, Ford & Dow Chemical

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular...

Lilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students

Eli Lilly and Company (NYSE:LLY) will deepen its partnership with Florida Agricultural and Mechanical University (FAMU) and Howard University with the inaugural Sybil C. Mobley Scholars Program and the...

J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.

Eli Lilly's Taltz Gaining Ground in Psoriasis Market, Leaving Novartis' Cosentyx at Risk in 2017, according to Spherix Global Insights

At just over six months post launch, US dermatologists report a significant increase in familiarity with Eli Lilly's IL-17 inhibitor, coupled with a significant increase in the Taltz user base from prior...

Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF

Lilly's (LLY) stock was hit by the company's announcement that its investigational Alzheimer's disease drug failed in a late-stage study.

Eli Lilly Hits 52-Week Low on Poor Data on Alzheimer's Drug

Eli Lilly's (LLY) shares touched a new 52-week low after its Alzheimer's disease candidate, solanezumab, failed to meet the primary endpoint in a phase III study.

Stock Market News for November 25, 2016

Benchmarks finished mixed on Wednesday after strong durable orders and Donald Trump’s economic agenda boosted the industrial sector

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research...

See More

Support & Resistance

2nd Resistance Point 67.93
1st Resistance Point 67.65
Last Price 67.38
1st Support Level 66.83
2nd Support Level 66.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.